Advanced search
Publication Cover
Ocular Immunology and Inflammation Volume 26, 2018 - Issue 8
Submit an article Journal homepage
586
Views
34
CrossRef citations to date
0
Altmetric
Original Articles

Rituximab Induction and Maintenance Treatment in Patients with Scleritis and Granulomatosis with Polyangiitis (Wegener’s)

Caiyun YouMassachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, USA;Ocular Immunology and Uveitis Foundation, Weston, Massachusetts, USA;Department of Ophthalmology, Tianjin Medical UniversityGeneral Hospital, Tianjin, China
, MD,
Lina MaMassachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, USA;Ocular Immunology and Uveitis Foundation, Weston, Massachusetts, USA
, MD,
Andres F. LasaveMassachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, USA;Ocular Immunology and Uveitis Foundation, Weston, Massachusetts, USA
, MD &
C. Stephen FosterMassachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, USA;Ocular Immunology and Uveitis Foundation, Weston, Massachusetts, USA;Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, USACorrespondence[email protected]
, MD, FACR, FACS
Pages 1166-1173 | Received 05 Jul 2016, Accepted 03 May 2017, Published online: 19 Jun 2017

References

  • Cocho L, Gonzalez-Gonzalez LA, Molina-Prat N, et al. Scleritis in patients with granulomatosis with polyangiitis (Wegener). Br J Ophthalmol. 2016;100(8):1062–1065.
  • Charlier C, Henegar C, Launay O, et al. Risk factors for major infections in Wegener granulomatosis: Analysis of 113 patients. Ann Rheum Dis. 2009;68(5):658–663.
  • Benucci M, Manfredi M, Puttini PSet al,Predictive factors of response to rituximab therapy in rheumatoid arthritis: What do we know today?. Autoimmun Rev. 2010;9(12):801–803.
  • Quartuccio L, Fabris M, Salvin Set al,Controversies on rituximab therapy in Sjogren syndrome-associated lymphoproliferation. Int J Rheumatol. 2009;2009:424935.
  • Piccio L, Naismith RT, Trinkaus Ket al,Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis. Arch Neurol. 2010;67(6):707–714.
  • Shaw T, Quan J, Totoritis MC. B cells therapy for rheumatoid arthritis: The rituximab (anti CD20) experience. Ann Rheum Dis. 2003;62(Suppl 2): ii55–59.
  • Condon MB, Ashby D, Pepper RJet al, Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis. 2013;72(8):1280–1286.
  • Joshi L, Tanna A, McAdoo SPet al, Long-term outcomes of rituximab therapy in ocular granulomatosis with polyangiitis: Impact on localized and nonlocalized disease. Ophthalmology. 2015;122(6):1262–1268.
  • Recillas-Gispert C, Serna-Ojeda JC, Flores-Suárez LF. Rituximab in the treatment of refractory scleritis in patients with granulomatosis with polyangiitis (Wegener’s). Graefes Arch Clin Exp Ophthalmol. 2015;253(12):2279–2284.
  • Suhler EB, Lim LL, Beardsley RM, et al. Rituximab therapy for refractory scleritis: Results of a phase I/II dose-ranging, randomized, clinical trial. Ophthalmology. 2014;121(10):1885–1891.
  • Taylor SR, Salama AD, Joshi L, et al. Rituximab is effective in the treatment of refractory ophthalmic Wegener’s granulomatosis. Arthritis Rheum. 2009;60(5):1540–1547.
  • Keogh KA, Wylam ME, Stone JH, et al. Induction of remission by Blymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2005;52(1):262–268.
  • Calich AL, Puéchal X, Pugnet G, et al. French Vasculitis Study Group. Rituximab for induction and maintenance therapy in granulomatosis with polyangiitis (Wegener’s). Results of a single-center cohort study on 66 patients. J Autoimmun. 2014;50:135–141.
  • Jones RB, Ferraro AJ, Chaudhry AN, et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2009;60(7):2156–2168.
  • McCluskey P, Wakefield D. Prediction of response to treatment in patients with scleritis using a standardised scoring system. Aust N Z J Ophthalmol. 1991;19(3):211–215.
  • Foster CS, Chang PY, Ahmed AR. Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid: a preliminary report. Ophthalmology. 2010;117(5):861–869.
  • Morarji J, Joshi L, Tomkins-Netzer O, et al. Combined infliximab and rituximab in necrotising scleritis. Case Rep Ophthalmol. 2012;3(3):286–290.
  • Onal S, Kazokoglu H, Koc A, et al. Rituximab for remission induction in a patient with relapsing necrotizing scleritis associated with limited Wegener’s granulomatosis. Ocul Immunol Inflamm. 2008;16(5):230–232.
  • Cheung CM, Murray PI, Savage CO. Successful treatment of Wegener’s granulomatosis associated scleritis with rituximab. Br J Ophthalmol. 2005;89(11):1542.
  • Bogdanic-Werner K, Fernandez-Sanz G, Alejandre Alba N, et al. Rituximab therapy for refractory idiopathic scleritis. Ocul Immunol Inflamm. 2013;21(4):329–332.
  • Ahmadi-Simab K, Lamprecht P, Nölle B, et al. Successful treatment of refractory anterior scleritis in primary Sjogren’s syndrome with rituximab. Ann Rheum Dis. 2005;64(7):1087–1088.
  • Chauhan S, Kamal A, Thompson RN, et al. Rituximab for treatment of scleritis associated with rheumatoid arthritis. Br J Ophthalmol. 2009;93(7):984–985.
  • Iaccheri B, Androudi S, Bocci EB, et al. Rituximab treatment for persistent scleritis associated with rheumatoid arthritis. Ocul Immunol Inflamm. 2010;18(3):223–225.
  • Kurz PA, Suhler EB, Choi D, et al. Rituximab for treatment of ocular inflammatory disease: A series of four cases. Br J Ophthalmol. 2009;93(4):546–548.
  • Little MA, Nightingale P, Verburgh CA, et al. European vasculitis study (EUVAS) group. Early mortality in systemic vasculitis: Relative contribution of adverse events and active vasculitis. Ann Rheum Dis. 2010;69(6):1036–1043.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.